Your browser doesn't support javascript.
loading
Hypopituitarism after Gamma Knife radiosurgery for pituitary adenomas: a multicenter, international study
Cordeiro, Diogo; Xu, Zhiyuan; Mehta, Gautam; Ding, Dale; Vance, Mary Lee; Kano, Hideyuki; Sisterson, Nathaniel; Yang, Huai-che; Kondziolka, Douglas; Lunsford, L. Dade; Mathieu, David; Barnett, Gene; Chiang, Veronica; Lee, John; Sneed, Penny; Su, Yan-Hua; Lee, Cheng-chia; Krsek, Michal; Liscak, Roman; Nabeel, Ahmed; El-Shehaby, Amr; Karim, Khaled; Reda, Wael; Martinez-Moreno, Nuria; Martinez-Alvarez, Roberto; Blas, Kevin; Grills, Inga; Lee, Kuei; Kosak, Mikulas; Cifarelli, Christopher; Katsevman, Gennadiy; Sheehan, Jason.
Afiliación
  • Cordeiro D; Department of Neurological Surgery, University of Virginia, Charlottesville, Virginia
  • Xu Z; Department of Neurological Surgery, University of Virginia, Charlottesville, Virginia
  • Mehta GU; Department of Neurological Surgery, University of Virginia, Charlottesville, Virginia
  • Ding D; Department of Neurological Surgery, University of Virginia, Charlottesville, Virginia
  • Vance ML; Department of Neurological Surgery, University of Virginia, Charlottesville, Virginia
  • Kano H; Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania
  • Sisterson N; Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania
  • Yang HC; Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania
  • Kondziolka D; Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania
  • Lunsford LD; Department of Neurosurgery, New York University, New York, New York
  • Mathieu D; Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania
  • Barnett GH; Department of Surgery, Division of Neurosurgery, Université de Sherbrooke, Centre de recherche du CHUS, Sherbrooke, Quebec, Canada
  • Chiang V; Department of Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, Ohio
  • Lee J; Department of Neurosurgery, Yale University, New Haven, Connecticut
  • Sneed P; Department of Neurosurgery, University of Pennsylvania, Philadelphia, Pennsylvania
  • Su YH; Department of Radiation Oncology, University of California, San Francisco, California
  • Lee CC; Department of Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan, Republic of China
  • Krsek M; Department of Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan, Republic of China
  • Liscak R; Department of Stereotactic and Radiation Neurosurgery, Na Homolce Hospital, Prague, Czech Republic
  • Nabeel AM; Department of Stereotactic and Radiation Neurosurgery, Na Homolce Hospital, Prague, Czech Republic
  • El-Shehaby A; Department of Neurosurgery, Faculty of Medicine, Benha University, Qalubya, Egypt
  • Karim KA; Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt
  • Reda WA; Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt
  • Martinez-Moreno N; Gamma Knife Center Cairo-Nasser Institute, Neurosurgery Department, Ain Shams University, Cairo, Egypt
  • Martinez-Alvarez R; Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt
  • Blas K; Gamma Knife Center Cairo-Nasser Institute, Neurosurgery Department, Ain Shams University, Cairo, Egypt
  • Grills I; Department of Functional Neurosurgery and Radiosurgery, Ruber International Hospital, Madrid, Spain
  • Lee KC; Department of Functional Neurosurgery and Radiosurgery, Ruber International Hospital, Madrid, Spain
  • Kosak M; Radiation Oncology Department, Beaumont Health System, Royal Oak, Michigan
  • Cifarelli CP; Radiation Oncology Department, Beaumont Health System, Royal Oak, Michigan
  • Katsevman GA; Radiation Oncology Department, Beaumont Health System, Royal Oak, Michigan
  • Sheehan JP; Third Department of Medicine, Department of Endocrinology and Metabolism, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
J Neurosurg ; 2018 11 09.
Article en En | MEDLINE | ID: mdl-31369225
OBJECTIVE: Recurrent or residual adenomas are frequently treated with Gamma Knife radiosurgery (GKRS). The most common complication after GKRS for pituitary adenomas is hypopituitarism. In the current study, the authors detail the timing and types of hypopituitarism in a multicenter, international cohort of pituitary adenoma patients treated with GKRS. METHODS: Seventeen institutions pooled clinical data obtained from pituitary adenoma patients who were treated with GKRS from 1988 to 2016. Patients who had undergone prior radiotherapy were excluded. A total of 1023 patients met the study inclusion criteria. The treated lesions included 410 nonfunctioning pituitary adenomas (NFPAs), 262 cases of Cushing's disease (CD), and 251 cases of acromegaly. The median follow-up was 51 months (range 6­246 months). Statistical analysis was performed using a Cox proportional hazards model to evaluate factors associated with the development of new-onset hypopituitarism. RESULTS: At last follow-up, 248 patients had developed new pituitary hormone deficiency (86 with NFPA, 66 with CD, and 96 with acromegaly). Among these patients, 150 (60.5%) had single and 98 (39.5%) had multiple hormone deficiencies. New hormonal changes included 82 cortisol (21.6%), 135 thyrotropin (35.6%), 92 gonadotropin (24.3%), 59 growth hormone (15.6%), and 11 vasopressin (2.9%) deficiencies. The actuarial 1-year, 3-year, 5-year, 7-year, and 10-year rates of hypopituitarism were 7.8%, 16.2%, 22.4%, 27.5%, and 31.3%, respectively. The median time to hypopituitarism onset was 39 months. In univariate analyses, an increased rate of new-onset hypopituitarism was significantly associated with a lower isodose line (p = 0.006, HR = 8.695), whole sellar targeting (p = 0.033, HR = 1.452), and treatment of a functional pituitary adenoma as compared with an NFPA (p = 0.008, HR = 1.510). In multivariate analyses, only a lower isodose line was found to be an independent predictor of new-onset hypopituitarism (p = 0.001, HR = 1.38). CONCLUSIONS: Hypopituitarism remains the most common unintended effect of GKRS for a pituitary adenoma. Treating the target volume at an isodose line of 50% or greater and avoiding whole-sellar radiosurgery, unless necessary, will likely mitigate the risk of post-GKRS hypopituitarism. Follow-up of these patients is required to detect and treat latent endocrinopathies.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Revista: J Neurosurg Año: 2018 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Revista: J Neurosurg Año: 2018 Tipo del documento: Article
...